Serum magnesium concentration is inversely associated with fibroblast growth factor 23 in haemodialysis patients

Nephrology

Volumn 19, Issue 11, 2014, Pages 667-671

  Iguchi, Akira ^a   Watanabe, Yasuo ^a   Iino, Noriaki ^b   Kazama, Junichiro James ^b   Iesato, Hiroshi ^c   Narita, Ichiei ^b  

^a Ojiya General Hospital   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c Ojiya General Hospital   (Japan)

Author keywords

Fibroblast growth factor 23; Haemodialysis; Magnesium oxide; Parathyroid hormone; Vitamin D

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CINACALCET; ERYTHROPOIETIN; FERRITIN; FIBROBLAST GROWTH FACTOR 23; INTACT PARATHYROID HORMONE; IRON; MAGNESIUM; MAGNESIUM OXIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D; FIBROBLAST GROWTH FACTOR;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE DISEASE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; BLOOD; COMPLICATION; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

AGED; BONE DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MAGNESIUM; MALE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84907899251     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12287     Document Type: Article

References (22)

1. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012; 82: 737-47.
2. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 2006; 91: 3144-9.
3. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 2006; 17: 1305-15.
4. López I, Rodríguez-Ortiz ME, Almadén Y. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 2011; 80: 475-82.
5. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal Physiol. 2005; 289: F1088-95.
6. David V, Dai B, Martin A, Huang J, Han X, Quarles LD. Calcium regulates FGF-23 expression in bone. Endocrinology 2013; 154: 4469-82.
7. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 359: 584-92.
8. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 2009; 24: 2792-6.
9. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-9.
10. Navarro-González JF, Mora-Fernández C, García-Pérez J et al. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin. Dial. 2009; 22: 37-44.
11. Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A. Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: A double-blind, randomized, placebo-controlled trial. Eur. Neurol. 2013; 69: 309-16.
12. Kanbay M, Goldsmith D, Uyar ME. Magnesium in chronic kidney disease: Challenges and opportunities. Blood Purif. 2010; 29: 280-92.
13. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int. 2005; 67: 1120-25.
14. Koiwa F, Kazama JJ, Tokumoto A. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther. Apher. Dial. 2005; 9: 336-9.
15. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2012; 27: 784-90.
16. Matsuzaki H, Kajita Y, Miwa M. Magnesium deficiency increases serum fibroblast growth factor-23 levels in rats. Magnes. Res. 2013; 26: 18-23.
17. van Angelen AA, San-Cristobal P, Pulskens WP, Hoenderop JG, Bindels RJ. The impact of dietary magnesium restriction on magnesiotropic and calciotropic genes. Nephrol. Dial. Transplant. 2013; 28: 2983-93.
18. Covic A, Passlick-Deetjen J, Kroczak M et al. A comparison of calcium acetate/magnesium carbonate and sevelamerhydrochloride effects on fibroblast growth factor-23 and bone markers: Post hoc evaluation from a controlled, randomized study. Nephrol. Dial. Transplant. 2013; 28: 2383-92.
19. Rodríguez-Ortiz ME, Canalejo A, Herencia C et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol. Dial. Transplant. 2014; 29: 282-9.
20. David V, Dai B, Martin A, Huang J, Han X, Quarles LD. Calcium regulates FGF23 expression in bone. Endocrinology 2013; 154: 4469-82.
21. Wang M, Berlin JR. Voltage-dependent modulation of L-type calcium currents by intracellular magnesium in rat ventricular myocytes. Arch. Biochem. Biophys. 2007; 458: 65-72.
22. Elizodo MR, Budi EH, Parichy DM. trpm7 regulation of in vivo cation homeostasis and kidney function involves stanniocalcin 1 and fgf23. Endocrinology 2010; 151: 5700-9.